August 19, 2025Open Access

Regional blood flow signatures of opioidergic modulation of ketamine in major depressive disorder: a randomised crossover study

View Full Paper

Ask AI

Bookmark

Ketamine significantly increased cerebral blood flow in regions linked to depression, not affected by naltrexone.
Under placebo, baseline cerebral blood flow predicted antidepressant response, highlighting its importance in treatment planning.
Crossover methodology involved administering either naltrexone or placebo before ketamine infusion, ensuring robust results.
Findings suggest intricate interactions among glutamatergic, opioidergic, and GABAergic systems, guiding future ketamine therapies.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Randomised crossover study explores how naltrexone modulates ketamine's effects on cerebral blood flow in MDD, indicating interaction between opioid and glutamatergic systems.

Cite This Study

Jelen et al. (2025) studied this question.

synapsesocial.com/papers/68af4093cf1dd9ea359ec5d0 https://doi.org/10.1101/2025.08.18.25333599

View Full Paper

Ask AI

Bookmark

Implication

Randomised crossover study explores how naltrexone modulates ketamine's effects on cerebral blood flow in MDD, indicating interaction between opioid and glutamatergic systems.

Regional blood flow signatures of opioidergic modulation of ketamine in major depressive disorder: a randomised crossover study

Key Points

Discussion

Implication

Cite This Study

Regional blood flow signatures of opioidergic modulation of ketamine in major depressive disorder: a randomised crossover study

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider